ABBV vs DGX: fair value comparison
AbbVie Inc. and Quest Diagnostics Incorporated · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, ABBV currently sits closer to the top of our ranking by discount to fair value.
| ABBV | DGX | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $276.47 | $230.97 |
| 12-month range | $197.38–$285.42 | $173.49–$247.45 |
| Rank by discount to fair value | #78 of 108 Healthcare | #82 of 108 Healthcare |
| Quality grade | B | B |
| Leverage | Low | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Overbought | Neutral |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: ABBV fair value analysis · DGX fair value analysis